Apobiologix’s Bambevi (biosimilar, bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications

Shots:

• Apobiologix expands its footprints in Canada with the approval of Bambevi + CT to treat colorectal, lung, brain and ovarian cancer
• The approval is coupled with well-established Apobiologix supportive care products that enable the company to transform access to affordable therapies in oncology and other indications
• In 2016, Apobiologix launched its first product, Grastofil (filgrastim) followed by the launch of Lapelga in 2019 in Canada. Additionally, Apobiologix is the first company to offer a portfolio of G-CSF biosimilars

Click here to­ read full press release/ article | Ref: Newswire | Image: Biospace